Sanofi and Regeneron expanded their long-running immunology alliance, moving four next-generation antibody programs into the shared portfolio and targeting pivotal testing in 2029. The update comes as both companies seek to extend beyond Dupixent as patent timelines approach. Separately, Sanofi committed $1B to widen the collaboration, framing the deal as a pipeline replenishment effort ahead of Dupixent’s 2031 patent expiration. The companies’ strategy aligns with a broader push to refresh large-molecule growth profiles with next-gen biologics while building shared development capacity across geographies. Taken together, the announcements highlight how big pharma continues to treat platform-style partnering as a hedge against clinical attrition—locking in multiple assets and timelines rather than betting on a single lead candidate.